Changes in tumour biological markers during primary systemic chemotherapy (PST)
- PMID: 18630463
Changes in tumour biological markers during primary systemic chemotherapy (PST)
Abstract
Background: The influence of primary systemic therapy (PST) on the expression of relevant therapeutic markers is still under investigation.
Patients and methods: Corresponding "baseline" biopsies and post-chemotherapy surgical specimens from 87 patients treated with neoadjuvant anthracycline- or taxane-based chemotherapy were analysed for the expression of the oestrogen receptor (ER), the progesterone receptor (PR), the B-cell lymphoma protein 2 (Bcl-2), the v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (Her2/neu), the tumour protein p53 and the proliferation-related Ki-67 antigen.
Results: The pathological response rate was 70%. Twenty-three tumours (26%) changed hormone receptor classification after chemotherapy (7, ER; 16 PR). A significant change was also observed for Her2/neu status. Eleven tumours which were positive prior to PST down-regulated Her2/neu after chemotherapy. The median Ki-67 index decreased from 30% before to 13% after treatment (p<0.01). Minor changes were observed in the expression of Bcl-2 and p53 (9%). Only the reduction of Ki-67 was associated with pathological response to PST.
Conclusion: Her2/neu status as well as ER and PR status should be re-evaluated on post-chemotherapy surgical specimens since changes can be observed.
Similar articles
-
Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.Anticancer Res. 2005 Nov-Dec;25(6C):4615-21. Anticancer Res. 2005. PMID: 16334152
-
Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.Anticancer Res. 2003 Jan-Feb;23(1B):565-8. Anticancer Res. 2003. PMID: 12680147
-
Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.Radiat Med. 2005 May;23(3):189-94. Radiat Med. 2005. PMID: 15940066
-
Predictive markers of response to neoadjuvant chemotherapy in breast cancer.Surg Oncol. 2008 Dec;17(4):301-11. doi: 10.1016/j.suronc.2008.03.003. Epub 2008 May 7. Surg Oncol. 2008. PMID: 18467090 Review.
-
[Neoadjuvant systemic chemotherapy for patients with operable breast cancer].Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):161-5. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 17649628 Review. Chinese. No abstract available.
Cited by
-
Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer.Cancers (Basel). 2022 Apr 23;14(9):2103. doi: 10.3390/cancers14092103. Cancers (Basel). 2022. PMID: 35565232 Free PMC article. Review.
-
Prognostic Value of Receptor Change After Neoadjuvant Chemotherapy in Breast Cancer Patients.Eur J Breast Health. 2022 Apr 1;18(2):167-171. doi: 10.4274/ejbh.galenos.2022.2022-1-4. eCollection 2022 Apr. Eur J Breast Health. 2022. PMID: 35445177 Free PMC article.
-
NMR-Based Metabolomics Analysis Predicts Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.Front Mol Biosci. 2021 Nov 2;8:708052. doi: 10.3389/fmolb.2021.708052. eCollection 2021. Front Mol Biosci. 2021. PMID: 34796199 Free PMC article.
-
Effect of neoadjuvant therapy on breast cancer biomarker profile.BMC Cancer. 2020 Jul 18;20(1):675. doi: 10.1186/s12885-020-07179-4. BMC Cancer. 2020. PMID: 32682413 Free PMC article.
-
Analysis of the molecular subtypes of preoperative core needle biopsy and surgical specimens in invasive breast cancer.J Pathol Transl Med. 2020 Jan;54(1):87-94. doi: 10.4132/jptm.2019.10.14. Epub 2019 Nov 13. J Pathol Transl Med. 2020. PMID: 31718121 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
